ABL Bio said on the 8th that &#39;tovecimig&#39; a cholangiocarcinoma treatment under development by its global partner Compass Therapeutics, received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA)

tovecimig (CTX-009) - ABL Bio, Compass Therap

Apr 8, 2026